Lupin launches generic Vigamox Ophthalmic solution in US

05 Jul 2017 Evaluate

Pharma Major Lupin has launched its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base) having received an approval from the United States Food and Drug Administration (USFDA) earlier.

Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.’s Vigamox Ophthalmic solution. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms. Vigamox Ophthalmic solution had US sales of $267.9 million as per IMS MAT March 2017.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2119.50 -31.55 (-1.47%)
01-Feb-2026 13:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1618.65
Dr. Reddys Lab 1225.20
Cipla 1318.20
Zydus Lifesciences 887.15
Lupin 2119.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×